Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. It develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. It is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.
企業コードBJDX
会社名Bluejay Diagnostics Inc
上場日Nov 10, 2021
最高経営責任者「CEO」Dey (Neil)
従業員数7
証券種類Ordinary Share
決算期末Nov 10
本社所在地360 Massachusetts Avenue, Suite 203
都市ACTON
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号01720
電話番号19786310152
ウェブサイトhttps://bluejaydx.com/
企業コードBJDX
上場日Nov 10, 2021
最高経営責任者「CEO」Dey (Neil)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし